The neuropathological scoring systems developed for MSA well correlate with the initial clinical presentation and with disease severity, but they do not take into account the progressive involvement of key autonomic nuclei and are not able to predict the disease progression and the spreading of the α-synuclein pathology. The gene discussed is SNCA; the disease is multiple system atrophy.